The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024.
Ore Huiying | Bloomberg | Getty Images
Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal.
The pharmaceutical giant now expects its adjusted fiscal 2025 earnings to come in between $20.78 and $22.28 per share, down from a previous guidance of $22.50 to $24 per share.
Eli Lilly maintained its fiscal 2025 sales guidance of $58 billion to $61 billion.
Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: $3.34 adjusted vs. $3.02 expected
- Revenue: $12.73 billion vs. $12.67 billion expected
This story is developing. Please check back for updates.
